[INARI] QoQ Cumulative Quarter Result on 30-Jun-2021 [#4]

Stock
[INARI] INARI AMERTRON BERHAD
Announcement Date
06-Aug-2021
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2021
Quarter
30-Jun-2021 [#4]
Profit Trend
QoQ- 36.5%
YoY- 112.18%
Quarter Report
Latest QR
Upcoming QR
INARI's Result
INARI's Financial Summary
View:
Show?
Cumulative Result
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Revenue 1,211,722 851,380 431,123 1,428,704 1,067,384 724,451 347,621 130.07%
PBT 338,124 235,046 118,322 352,249 258,854 172,127 77,414 167.44%
Tax -32,896 -20,102 -11,429 -21,534 -16,812 -11,977 -7,349 171.85%
NP 305,228 214,944 106,893 330,715 242,042 160,150 70,065 166.97%
-
NP to SH 304,701 214,226 106,927 330,473 242,113 160,167 70,070 166.65%
-
Tax Rate 9.73% 8.55% 9.66% 6.11% 6.49% 6.96% 9.49% -
Total Cost 906,494 636,436 324,230 1,097,989 825,342 564,301 277,556 120.28%
-
Net Worth 2,474,164 2,471,735 2,361,245 1,371,846 1,385,890 1,313,852 1,254,151 57.36%
Dividend
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Div 288,942 206,777 100,341 367,787 281,954 148,178 65,252 169.90%
Div Payout % 94.83% 96.52% 93.84% 111.29% 116.46% 92.52% 93.12% -
Equity
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Net Worth 2,474,164 2,471,735 2,361,245 1,371,846 1,385,890 1,313,852 1,254,151 57.36%
NOSH 3,705,170 3,702,338 3,684,841 3,346,436 3,338,921 3,300,592 3,271,213 8.66%
Ratio Analysis
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
NP Margin 25.19% 25.25% 24.79% 23.15% 22.68% 22.11% 20.16% -
ROE 12.32% 8.67% 4.53% 24.09% 17.47% 12.19% 5.59% -
Per Share
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
RPS 32.71 23.06 12.03 42.73 32.18 22.00 10.65 111.43%
EPS 8.33 5.89 2.98 10.01 7.36 4.89 2.15 146.88%
DPS 7.80 5.60 2.80 11.00 8.50 4.50 2.00 147.97%
NAPS 0.6679 0.6694 0.6589 0.4103 0.4178 0.399 0.3844 44.57%
Adjusted Per Share Value based on latest NOSH - 3,346,436
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
RPS 31.99 22.47 11.38 37.71 28.18 19.12 9.18 130.02%
EPS 8.04 5.65 2.82 8.72 6.39 4.23 1.85 166.54%
DPS 7.63 5.46 2.65 9.71 7.44 3.91 1.72 170.22%
NAPS 0.6531 0.6525 0.6233 0.3621 0.3658 0.3468 0.3311 57.34%
Price Multiplier on Financial Quarter End Date
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Date 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 -
Price 3.07 4.00 3.69 3.17 3.28 2.76 2.28 -
P/RPS 9.39 17.35 30.67 7.42 10.19 12.55 21.40 -42.28%
P/EPS 37.32 68.95 123.67 32.07 44.94 56.74 106.16 -50.22%
EY 2.68 1.45 0.81 3.12 2.23 1.76 0.94 101.19%
DY 2.54 1.40 0.76 3.47 2.59 1.63 0.88 102.85%
P/NAPS 4.60 5.98 5.60 7.73 7.85 6.92 5.93 -15.58%
Price Multiplier on Announcement Date
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Date 13/05/22 18/02/22 12/11/21 06/08/21 21/05/21 24/02/21 24/11/20 -
Price 2.56 3.20 4.00 3.60 3.00 3.28 2.47 -
P/RPS 7.83 13.88 33.25 8.42 9.32 14.91 23.18 -51.52%
P/EPS 31.12 55.16 134.06 36.42 41.10 67.43 115.01 -58.19%
EY 3.21 1.81 0.75 2.75 2.43 1.48 0.87 138.96%
DY 3.05 1.75 0.70 3.06 2.83 1.37 0.81 142.22%
P/NAPS 3.83 4.78 6.07 8.77 7.18 8.22 6.43 -29.22%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment